La cadena de opciones muestra datos clave de las opciones de acciones de iSpecimen a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para iSpecimen..

iSpecimen (NASDAQ:ISPC) Bolsa, Cadena de Opciones

iSpecimen

iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ALVO

BBGI

BCAX

ELTX

FOXO

ISPC

JBHT

LYTS

MDXG

NATR

NUKK

OFIX

TMCI

TXNM

VIAV

WILC

Explora los mayores ganadores y perdedores en las operaciones previas al mercado. Descubre qué impulsó estos movimientos destacados.

Las acciones de Versus Systems (VS) aumentan un 71%; 20 acciones que se mueven en el premercado de EE.UU.

iSpecimen Inc

ISHARES PLC SHS ORD by IShares Plc.

Upon Gresham Worldwide's emergence from bankruptcy, Hyperscale Data expects to reconsolidate Gresham Worldwide's financial results into its financial statements and anticipates that Gresham Worldwide will contribute up to an additional $10 million in consolidated revenue in the fourth quarter of 2025. If the reconsolidation of Gresham Worldwide had occurred on January 1, 2025, on a pro forma basis, a non-GAAP financial measure, this reconsolidation would have been expected to increase the Company's annualized revenue for 2025 by approximately $40 million.
In connection with the anticipated reconsolidation, Hyperscale Data has raised its full-year 2025 GAAP basis revenue guidance to a range of $125 million to $135 million. The table below presents pro forma figures, which are not necessarily consistent with GAAP, that show the expected revenue run rate including an annualized contribution from Gresham Worldwide:

Guidance

GPUS

Hyperscale Data Raises Its FY25 GAAP Basis Revenue Guidance To A Range Of $125M-$135M

Compass Point analyst Ed Engel initiates coverage on Antalpha Platform Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTA#NASDAQ">ANTA</a>) with a Buy rating and announces Price Target of $20.

Price Target

Initiation

Analyst Ratings

ANTA

Compass Point Initiates Coverage On Antalpha Platform Holding with Buy Rating, Announces Price Target of $20

Marion Advanced Technology Center positioned to become the largest multi-mineral, multi-feedstock rare earth and critical mineral refinery in the United States
EXIM's support of the proposed capital funding plan for the Marion Advanced Technology Center advances the "Make More In America" initiative amid rising competition from China in critical mineral supply chains
FISHERS, IN / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 9, 2025 / American Resources Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREC#NASDAQ">AREC</a>) ("American Resources"), through its holding in ReElement Technologies Corporation ("ReElement" or "RTC"), a leading U.S. innovator in rare earth element (REE) and critical mineral refining, announced today that it has received support for the proposed capital funding plan by ReElement Technologies Corporation for the Marion Advanced Technology through a Letter of Interest (LOI) from the <a href="https://pr.report/ba7f">Export-Import Bank of the United States</a> (EXIM) for up to $150 million in financing. This financing will support the expansion of ReElement's state-of the-art rare earth, critical mineral and defense mineral refining project that is set to become the nation's largest multi-mineral, multi-feedstock rare earth and critical mineral refinery. The Marion facility builds on ReElement's successful commercial operations in its Noblesville, Indiana facility supplying highly refined critical mineral products to both the commercial and defense markets.

AREC

American Resources' Reelement Receives Support For Proposed Capital Funding Plan For Marion Advanced Technology Through LOI From Export-Import Bank Of The United States For Up To $150M

Compass Point analyst Casey Alexander downgrades Saratoga Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAR#NYSE">SAR</a>) from Buy to Neutral and lowers the price target from $25.25 to $24.25.

Downgrades

Compass Point Downgrades Saratoga Investment to Neutral, Lowers Price Target to $24.25

Will provide expertise across ModeX's portfolio of next generation multispecific antibodies for complex diseases involving the immune system, including cancer
ModeX's promising immunology pipeline includes first-in class drugs with two assets in ongoing clinical trials and multiple pre-IND assets to enter clinical trials
WESTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>), today announced the creation of a Scientific Advisory Board to provide counsel and insight into the development of ModeX's immunology and oncology-focused pipeline featuring potential first-in-class multispecific antibodies and vaccines developed with its proprietary MSTAR platform technology. Aligned with the company's primary areas of focus, the board is comprised of established leaders across complex diseases involving the immune system including cancer, immune-mediated disease, and infectious diseases.
The founding members include Drs. John Heymach, Ronald Levy, Myron Cohen, and Rafi Ahmed. Each of these globally recognized researchers brings notable contributions to biomedical research and the translation of therapeutics to impact public health.

Biotech

General

OPKO Health's ModeX Therapeutics Forms Scientific Advisory Board To Guide Development Of Next-Gen Multispecific Antibodies For Cancer And Immune Diseases

Legal

ICCM

IceCure Gets Notice Of Patent Allowance In U.S. Titled 'Cryogen Flow Control'

FibroBiologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Jason D. Davis, CPA, as Chief Financial Officer, effective immediately.
Mr. Davis brings extensive experience in corporate finance, capital markets, and SEC reporting, with a proven track record of successfully leading companies through critical growth phases, including IPOs and capital raising initiatives. His appointment comes as FibroBiologics advances toward its Phase 1/2 clinical trial for diabetic foot ulcers in the second half of 2025 and continues to expand its fibroblast-based therapeutic platform.

Management

FBLG

FibroBiologics Announces The Appointment Of Jason D. Davis As Chief Financial Officer, Effective Immediately

An&nbsp;extensive range of solutions from Sabre's Raddix suit will support Vietravel Airlines' future growth
SINGAPORE and HUẾ, Vietnam, June 9, 2025 /PRNewswire/ -- Vietravel Airlines has renewed its Passenger Service System (PSS) agreement with <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4444039-1&amp;h=2284763656&amp;u=http%3A%2F%2Fwww.sabre.com%2F&amp;a=Sabre+Corporation">Sabre Corporation</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABR#NASDAQ">SABR</a>), a leading global travel technology company, for another five years – underscoring the airline's confidence in Sabre's Radixx platform as a key enabler for growth.&nbsp;&nbsp;&nbsp;
Vietravel Airlines constitutes an integral component of the aviation and logistics ecosystem of T&amp;T Group. This integration was solidified in December 2024 when T&amp;T Group became a strategic shareholder of Vietravel Airlines, positioning T&amp;T as the first conglomerate in Vietnam to possess both airport and airline assets concurrently. T&amp;T Group is currently developing a comprehensive investment strategy to realize its objective of establishing Vietravel Airlines as a leading regional carrier, with a dual focus on expanding passenger transport and pioneering the development of air cargo services.

SABR

Vietravel Airlines Renews Passenger Service System Agreement With Sabre For Another Five Years

Contracts

iPower Makes Deposit Payment To Initiate Production Of New Equipment Line; Terms Not Disclosed

Microbot Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>), developer of the innovative LIBERTY Endovascular Robotic System, today announced the continued expansion of its commercial team in preparation for the anticipated U.S. launch of the LIBERTY System, which is projected during the third quarter of 2025. The Company remains actively engaged with the U.S. Food and Drug Administration (FDA), with a 510(k) decision now expected during the third quarter of this year. This updated FDA decision timeline remains within the FDA's original scheduled review window and is not expected to affect the Company's planned launch upon clearance.

MBOT

Microbot Medical Expands Commercial Team Ahead Of Anticipated Q3 2025 U.S. Launch of LIBERTY Robotic System; FDA 510(k) Decision Expected Q3 2025

WIIM

MTSR

Metsera shares are trading higher after the company announced  topline data from the Phase 1 clinical trial of MET-233i.

<ul>
<li>Product line includes Druck, Panametrics and Reuter-Stokes brands</li>
<li>Transaction aligns with Baker Hughes' ongoing portfolio optimization</li>
</ul>
HOUSTON and LONDON, June 09, 2025 (GLOBE NEWSWIRE) -- Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>), an energy technology company, announced Monday an agreement to sell its Precision Sensors &amp; Instrumentation (PSI) product line to Crane Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CR#NYSE">CR</a>, "Crane"))), a diversified manufacturer of engineered industrial products, for a total cash consideration of approximately $1.15 billion.
PSI, part of Baker Hughes' Industrial &amp; Energy Technology (IET) segment, includes the Druck, Panametrics and Reuter-Stokes brands. These brands manufacture instrumentation and sensor-based technologies to detect and analyze pressure, flow, gas, moisture and radiation across various industries. PSI employs approximately 1,600 people across several&nbsp;manufacturing and service facilities globally. The sale encompasses all assets of the business, including intellectual property, footprint and resources.

Baker Hughes Agrees To Sell Precision Sensors & Instrumentation Product Line To Crane For Total Cash Consideration Of About $1.15B

Siebert Financial Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIEB#NASDAQ">SIEB</a>) today announced that its shelf registration statement on Form S-3 has been declared effective by the SEC. The registration is the first step to allow the company to raise up to $100,000,000 through the sale of a range of securities.
The filing strengthens Siebert's financial flexibility. The proceeds may be used to pursue strategic initiatives that align with Siebert's long-term vision, including potential acquisitions, the purchase of digital assets (including Bitcoin, Ethereum, and Solana), and investments to advance technology across all service lines, including, but not limited to, AI-powered solutions.

Offerings

SIEB

Siebert Financial Secures $100M Shelf Registration Approval From SEC To Fuel Strategic Growth, Potential Acquisitions, Digital Asset Purchases, And AI-Driven Tech Investments

Argus Research analyst Bill Selesky downgrades Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from Buy to Hold.

TSLA

Argus Research Downgrades Tesla to Hold

Maravai LifeSciences Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William "Trey" Martin III in these roles.

MRVI

Maravai LifeSciences  Announces The Appointment Of Bernd Brust As Chief Executive Officer, Effective Immediately

As China&#8217;s May export data missed expectations just ahead of the <a href="https://www.benzinga.com/news/politics/25/06/45832550/us-and-china-resume-trade-talks-in-london-after-trumps-call-with-xi-jinping">second round of U.S.-China</a> trade negotiations, leading experts are offering sharply divergent interpretations of how the data will be leveraged during the trade talks. 
What Happened: While Mohamed A. El-Erian, a senior economist and former CEO of PIMCO, has sounded an alarm over &#8220;worrisome&#8221; figures, Bob Elliott, the CIO at Unlimited Funds, suggests China faces &#8220;little urgency&#8221; to concede.
According to El Erian, recent Chinese trade and inflation data were particularly troubling as May&#8217;s export figures fell below consensus forecasts.
The exports in May grew by 4.8%, missing the expected 5%, &#8220;it highlights the growing pressures the Chinese economy is under,&#8221; said El Erian.
Despite a rise in trade surplus by 25% compared to the previous year, El Erian noted that inflation in China experienced its &#8220;fourth consecutive month of negative readings,&#8221; falling by 0.1%, and producer price index inflation registered a negative 3.3%.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Worrisome Chinese trade and inflation data ahead of the country's negotiations with the US this week: China's exports and imports for May came in below the consensus forecast, primarily due to the sharp decline in trade with the US. Driven by an 18.5% drop, China's imports…
&mdash; Mohamed A. El-Erian (@elerianm) <a href="https://twitter.com/elerianm/status/1931985470046490947?ref_src=twsrc%5Etfw">June 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
In stark contrast, Elliott presented a more sanguine view, asserting that despite U.S. tariffs on Chinese goods &#8220;running at 30%,&#8221; recent data shows &#8220;little indication of a slowdown in the Chinese economy.&#8221; He believes these &#8220;stable economic conditions suggest little urgency for the Chinese to make a disadvantageous deal&#8221; in the ongoing trade talks.
He attributed this resilience to China&#8217;s strategic redirection of its export capacity &#8220;away from the US and to other jurisdictions.&#8221; While exports to the U.S. have indeed fallen by 34.5%, Elliott highlighted that &#8220;exports to other locations are up 11.4%.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">A big reason for this is that the Chinese have redirected their export capacity away from the US and to other jurisdictions. Exports to the US have fallen 34.5%, while exports to other locations are up 11.4%. <a href="https://t.co/EEIM5i8ydR">pic.twitter.com/EEIM5i8ydR</a>
&mdash; Bob Elliott (@BobEUnlimited) <a href="https://twitter.com/BobEUnlimited/status/1932011756701831277?ref_src=twsrc%5Etfw">June 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
He concluded his analysis by stating, &#8220;The export data, timely surveys and markets mostly point to the same picture: China is hanging in there just fine despite the high tariffs.&#8221;
See Also: <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45832125/as-trump-flames-powell-for-holding-back-on-rate-cuts-economists-divided-on-feds-app">As Trump Flames Powell For Holding Back On Rate Cuts, Economists Divided On Fed&#8217;s Approach</a>
Why It Matters: As U.S. and Chinese negotiators begin talks, these sharply differing interpretations of China&#8217;s economic resilience or fragility will undoubtedly color the approach of both sides, particularly regarding Beijing&#8217;s willingness to make concessions.
According <a href="https://www.bbc.com/news/articles/cql2x6d2zkgo?ref=biztoc.com">to</a> the BBC, U.S. Treasury Secretary Scott Bessent, Commerce Secretary Howard Lutnick, and Trade Representative Jamieson Greer will represent Washington in talks, facing a Beijing delegation led by Chinese Vice Premier He Lifeng.
Last week&#8217;s <a href="https://www.benzinga.com/news/politics/25/06/45793852/trump-reaches-out-to-xi-as-markets-react-tensions-simmer">phone call</a> between President Donald Trump and Chinese President Xi Jinping, described by Trump as having reached &#8220;a very positive conclusion for both countries,&#8221; paved the way for this meeting.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were flat in premarket on Monday. The SPY was up 0.12% at $599.88, while the QQQ advanced 0.055% to $530.21, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pr</a>o data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45834012/tom-lee-dismisses-worries-over-tumbling-tsla-stock-amid-elon-musk-trump-feud-tesla-still-holds-all-of-its-advantages-so-we-arent-too-concerned">Tom Lee Dismisses Worries Over Tumbling TSLA Stock Amid Elon Musk-Trump Feud: &#8216;Tesla Still Holds All Of Its Advantages, So We Aren&#8217;t Too Concerned&#8217;</a> 
<div class="flex flex-col w-full items-start lg:flex-row" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgb(59 130 246/0.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; display: flex; width: 734.667px; flex-direction: row; align-items: flex-start; color: rgb(45, 45, 45); font-family: Manrope, Manrope-fallback, sans-serif; font-size: 16px; white-space-collapse: collapse; background-color: rgb(25, 41, 64);">
<div class="sc-csAPp iLLqxH article-submitted flex flex-grow" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgb(59 130 246/0.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; display: inline-block; flex-grow: 1; font-size: 14px; margin-bottom: 0.3rem;">
<div class="article-submitted-content flex-wrap" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgb(59 130 246/0.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; flex-wrap: wrap;">
<div class="article-author-wrap flex items-center gap-1 text-gray-300" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgb(59 130 246/0.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ; display: flex; align-items: center; gap: 0.25rem; --tw-text-opacity: 1; color: rgb(209, 213, 219);"><span class="author" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgb(59 130 246/0.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;"></div>
</div>
</div>
</div>
</li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. 
Photo: Shutterstock

Mohamed El Erian Warns Of 'Worrisome' Chinese Trade Data Looming Over US Negotiations, But Bob Elliott Sees 'Little Urgency' For China To Sign A 'Disadvantageous Deal'

SVRE

SaverOne Signs Agreement With CEMEX Germany TO Install Distraction Prevention System In Fleet; Terms Not Disclosed

Latin Metals Says Social & Environmental Impact Report Approved For Exploration Drilling At Organullo Gold Project; Project Is Subject To Option Agreement With AngloGold Argentina

Results demonstrated that nicotinamide riboside (NR) significantly elevated NAD+ levels and improved multiple clinical markers in people with Werner Syndrome
Niagen Bioscience expands rare disease research portfolio, supporting further investigation of NAD+ augmentation with NR as a therapeutic strategy in rare progeroid diseases
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.niagenbioscience.com%2F&amp;esheet=54270907&amp;newsitemid=20250609224907&amp;lan=en-US&amp;anchor=Niagen+Bioscience%2C+Inc.&amp;index=1&amp;md5=bcc4904866607819935aeb730f09527a">Niagen Bioscience, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAGE#NASDAQ">NAGE</a>) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, shares positive results from a clinical study published in the peer-reviewed journal <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2F10.1111%2Facel.70093&amp;esheet=54270907&amp;newsitemid=20250609224907&amp;lan=en-US&amp;anchor=Aging+Cell&amp;index=2&amp;md5=0de55267efd21a5532f842506f5cfbac">Aging Cell</a>, by a team led by Masaya Koshizaka, M.D., Ph.D., Associate Professor, and Koutaro Yokote, M.D., Ph.D., MBA, President of Chiba University, both of the Center for Preventive Medical Sciences, Chiba University, and the Department of Diabetes, Metabolism and Endocrinology, Chiba University Hospital, Japan. This is the first study to demonstrate the safety and efficacy of Niagen Bioscience's patented nicotinamide riboside (NR) ingredient, Niagen&#xAE;, in individuals with Werner syndrome (WS), a rare genetic disorder marked by rapid aging and premature mortality.
The newly published double-blind, placebo-controlled study found that daily supplementation with Niagen significantly elevated blood NAD+ levels by approximately 140% and improved multiple clinical markers of cardiovascular and skin health in individuals with WS. Affecting approximately 1 in 380,000 to 1 in 1,000,000 people globally (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1514%2F&amp;esheet=54270907&amp;newsitemid=20250609224907&amp;lan=en-US&amp;anchor=GeneReviews&amp;index=3&amp;md5=e1b838366440be09054963765afcfd2e">GeneReviews</a>), Werner syndrome is caused by mutations that impair DNA repair, leading to cellular aging decades ahead of normal progression.

NAGE

Niagen Bioscience Reports Study Showing Niagen (NR) Boosts NAD+ Levels By 140% And Improves Clinical Markers In Werner Syndrome, Expanding Rare Disease Research Portfolio

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/06/06/final-trades-amazon-jefferies-financial-e-l-f-beauty-and-ventas.html">Halftime Report Final Trades</a>,&#8221; Kevin Simpson, CIO of Capital Wealth Planning, said e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) reported a 28% surge in full-year sales, also recording growth for 25 straight quarters.
Supporting his view, Truist Securities analyst Bill Chappell maintained e.l.f. Beauty with a Buy and raised the price target from $125 to $130, while Baird analyst Joel Beatty maintained the stock with an Outperform rating and boosted the price target from $110 to $145 on Friday.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Joshua Brown, CEO of Ritholtz Wealth Management, said he likes Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>). The stock is breaking out here at $211 and there is no resistance until $<a href="https://www.benzinga.com/quote/AMZN/analyst-ratings">240, he added</a>.
Supporting his view, Bank of America Securities analyst Justin Post maintained a Buy rating on Amazon.com with a price target of $248 on Friday.
Rob Sechan, CEO of NewEdge Wealth, said Jefferies Financial Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JEF#NYSE">JEF</a>) has a very low valuation.
Lending support to his choice, Goldman Sachs analyst James Yaro, on May 15, maintained Jefferies Financial with a Buy and raised the price target from $55 to $62.
Jenny Van Leeuwen Harrington, Chief Executive Officer of Gilman Hill Asset Management, LLC, named Ventas, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>), a REIT, as her final trade, which has a 3% yield.
On the earnings front, Ventas, on April 30, posted better-than-expected results for the first quarter.
Price Action:
<ul class="wp-block-list">
<li>Amazon shares gained 2.7% to close at $213.57 on Friday.</li>
<li>Jefferies Financial rose 2.7% to close at $52.41 on Friday.</li>
<li>e.l.f. Beauty gained 1.6% to settle at $117.66 during the session.</li>
<li>Ventas shares rose 0.5% to settle at $63.64.</li>
</ul>
Check This Out:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45811726/cramer-says-hes-not-going-to-really-want-to-do-a-lot-of-china-right-now">Cramer Says He&#8217;s &#8216;Not Going To Really Want To Do A Lot Of China Right Now&#8217;</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

AMZN

E.l.f. Beauty, Amazon, Jefferies Financial And More On CNBC's 'Final Trades'

Press Releases

iSpecimen Announces 1-for-20 Reverse Stock Split

Financing

iSpecimen Secures $1 Million Loan; Appoints Three New Board Members

Top Innovation Stocks Surge: PRSO, SYTA, SAVE, ISPC, GRI, BIVI – Must-Watch Stocks This Week

iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants

iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants

Earnings

iSpecimen Reports Third Quarter 2024 Results

Health Care

iSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 Annually

iSpecimen Inc. Stocks 48% Premarket Surge On Thursday Ignited A Regular Session Rally

iSpecimen Inc. Stock Surges After Announcing Expanded Cancer Biospecimen Offerings

iSpecimen Inc. Earns Investor Attention After Launching Milestone Cancer Biospecimen Offering

Comments

iSpecimen

iSpecimen (ISPC) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL